Arch Therapeutics Inc (NASDAQ:ARTH) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Arch Therapeutics Inc (NASDAQ:ARTH) have been given an average rating of “Hold” by the six ratings firms that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $2.83.

A number of research analysts have recently weighed in on the stock. ValuEngine raised shares of Arch Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 3rd. Ifs Securities reissued an “outperform” rating on shares of Arch Therapeutics in a research note on Tuesday, July 25th. Roth Capital set a $3.00 price objective on shares of Arch Therapeutics and gave the stock a “buy” rating in a research note on Thursday, May 25th. Zacks Investment Research cut shares of Arch Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 25th. Finally, HC Wainwright set a $3.00 price objective on shares of Arch Therapeutics and gave the stock a “buy” rating in a research note on Monday, June 12th.

WARNING: “[[title]]” was posted by [[site]] and is the property of of [[site]]. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at [[permalink]].

Arch Therapeutics (NASDAQ ARTH) traded down 0.36% during midday trading on Friday, reaching $0.69. The company’s stock had a trading volume of 106,407 shares. The company’s market cap is $101.44 million. Arch Therapeutics has a 12-month low of $0.41 and a 12-month high of $0.80. The firm has a 50 day moving average price of $0.63 and a 200-day moving average price of $0.59.

Arch Therapeutics Company Profile

Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.